Valuation : NeoGenomics, Inc.

Market Cap 2.24B 1.93B 1.81B 1.66B 3.09B 212B 3.12B 21.4B 8.34B 109B 8.42B 8.24B 350B P/E 2026 *
-58.5x
P/E 2027 * -71.5x
Enterprise Value 2.24B 1.93B 1.81B 1.66B 3.09B 212B 3.12B 21.4B 8.34B 109B 8.42B 8.24B 350B EV / Sales 2026 *
2.79x
EV / Sales 2027 * 2.53x
Free-Float
96.14%
Yield 2026 *
-
Yield 2027 * -
1 day+0.34%
1 week+0.52%
Current month-2.51%
1 month+14.19%
3 months+72.53%
6 months+83.79%
Current year+48.47%
1 week 17.05
Extreme 17.0542
18.75
1 month 15.48
Extreme 15.475
19.76
Current year 7.06
Extreme 7.065
19.76
1 year 7.06
Extreme 7.065
19.76
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Chairperson

67,272 0.0524%
8/4/26 Sell

Controller/Auditor

-20,000 0.0156%
6/23/26 Free

Director

23,909 0.0184%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%+0.52%+98.18%+15.10% 2.24B
+0.77%-3.19%+93.50%+424.10% 46.87B
-0.05%-1.26%+21.08%+60.47% 26.9B
+3.04%-3.79%-18.74%-40.06% 6.64B
-1.43%-2.42%+6.13%+129.11% 5.96B
+0.47%-0.62%+19.27%+74.92% 3.39B
+0.77%-3.21%-31.82%+1,844.16% 2.59B
+7.60%+7.26%+30.52%+36.18% 2.09B
-0.11%-5.74%-13.79%-55.37% 1.83B
-0.73%-6.88%+2.43%-21.84% 1.62B
Average +1.07%-1.84%+20.68%+246.68% 10.01B
Weighted average by Cap. +0.65%-3.22%+51.00%+269.70%

Financials

2026 *2027 *
Net sales 804M 692M 650M 595M 1.11B 75.96B 1.12B 7.67B 2.99B 38.93B 3.02B 2.95B 126B 885M 761M 715M 654M 1.22B 83.61B 1.23B 8.44B 3.29B 42.85B 3.32B 3.25B 138B
Net income -39.05M -33.6M -31.55M -28.88M -53.85M -3.69B -54.24M -373M -145M -1.89B -147M -143M -6.1B -32.73M -28.15M -26.44M -24.2M -45.13M -3.09B -45.45M -312M -122M -1.58B -123M -120M -5.11B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-09-03 US$17.46 +0.34% 2,217,548
26-09-02 US$17.40 -0.29% 1,794,476
26-09-01 US$17.45 -2.57% 1,318,286
26-08-31 US$17.91 -0.78% 1,579,101
26-08-28 US$18.05 -3.17% 1,723,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.46USD
Average target price
19.72USD
Spread / Average Target
+12.96%

Quarterly revenue - Rate of surprise